Evidence map›Paper›PMID 38664597›Full record

ReviewClinical and translational medicine2024

Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.

Jie Mei, Xingjian Liu, Hui-Xiang Tian, Yixuan Chen, Yang Cao, Jun Zeng, Yung-Chiang Liu, Yaping Chen, Yang Gao, Ji-Ye Yin and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jie Mei *Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.ORCID 0000-0002-8221-199X
Xingjian Liu *Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.
Hui-Xiang Tian *Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.ORCID 0009-0007-3632-636X
Yixuan ChenOujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.
Yang CaoOujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.
Jun ZengOujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.
Yung-Chiang LiuOujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.
Yaping ChenOujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.
Yang GaoNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Ji-Ye YinDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.ORCID 0000-0002-1244-5045
Peng-Yuan WangOujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.ORCID 0000-0001-7965-2914
Wenzhou Medical University · CNCentral South University · CN

Funding

Chinese Academy of Sciences 172644KYSB20200002Chinese Academy of Sciences 172644KYSB20200048Health research project of Hunan Province 20233013Ministry of Science and Technology of China 2022YFA1105101National Clinical Research Center for Geriatric Disorders 2021LNJJ17National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases z027002National Natural Science Foundation of China 82073943National Natural Science Foundation of China 82373962Natural Science Foundation of Hunan Province 2022JJ30925Scientific research project of Furong laboratory of Central South University 2023SK2083Zhejiang Provincial Natural Science Foundation of China LZ23C070004
6 · The paper itself

Abstract

backgroundOrganoid technology is an emerging and rapidly growing field that shows promise in studying organ development and screening therapeutic regimens. Although organoids have been proposed for a decade, concerns exist, including batch-to-batch variations, lack of the native microenvironment and clinical applicability. MAIN BODY: The concept of organoids has derived patient-derived tumour organoids (PDTOs) for personalized drug screening and new drug discovery, mitigating the risks of medication misuse. The greater the similarity between the PDTOs and the primary tumours, the more influential the model will be. Recently, 'tumour assembloids' inspired by cell-coculture technology have attracted attention to complement the current PDTO technology. High-quality PDTOs must reassemble critical components, including multiple cell types, tumour matrix, paracrine factors, angiogenesis and microorganisms. This review begins with a brief overview of the history of organoids and PDTOs, followed by the current approaches for generating PDTOs and tumour assembloids. Personalized drug screening has been practised; however, it remains unclear whether PDTOs can predict immunotherapies, including immune drugs (e.g. immune checkpoint inhibitors) and immune cells (e.g. tumour-infiltrating lymphocyte, T cell receptor-engineered T cell and chimeric antigen receptor-T cell). PDTOs, as cancer avatars of the patients, can be expanded and stored to form a biobank.

conclusionFundamental research and clinical trials are ongoing, and the intention is to use these models to replace animals. Pre-clinical immunotherapy screening using PDTOs will be beneficial to cancer patients. KEY POINTS: The current PDTO models have not yet constructed key cellular and non-cellular components. PDTOs should be expandable and editable. PDTOs are promising preclinical models for immunotherapy unless mature PDTOs can be established. PDTO biobanks with consensual standards are urgently needed.

Indexed as

ImmunotherapyNeoplasmsOrganoidsHumansPrecision Medicineassembloidcell therapyimmunotherapyorganoidPDTO biobank

Identifiers

PMID38664597
PMCPMC11045561
OpenAlexW4395672159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.